Melanoma NOS1 expression promotes dysfunctional IFN signaling

Journal of Clinical Investigation

Volumn 124, Issue 5, 2014, Pages 2147-2159

  Liu, Qiuzhen ^a,b   Tomei, Sara ^c   Ascierto, Maria Libera ^a   De Giorgi, Valeria ^a   Bedognetti, Davide ^a   Dai, Cuilian ^d   Uccellini, Lorenzo ^e   Spivey, Tara ^f   Pos, Zoltan ^g,h   Thomas, Jaime ^a   Reinboth, Jennifer ^a   Murtas, Daniela ^a   Zhang, Qianbing ^b   Chouchane, Lotfi ^c   Weiss, Geoffrey R ^j   Slingluff, Craig L ^j   Lee, Peter P ^k   Rosenberg, Steven A ^l   Alter, Harvey ^a   Yao, Kaitai ^b   Wang, Ena ^a,i   Marincola, Francesco M ^a,i   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^d XIAMEN UNIVERSITY   (China)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^j UNIVERSITY OF VIRGINIA   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA2 INTERFERON; JANUS KINASE 1; JANUS KINASE 2; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; STAT1 PROTEIN;

ARTICLE; CHROMOSOME 12Q; COCULTURE; COMPARATIVE GENOMIC HYBRIDIZATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; FILTERS AND MEMBRANES; GENE; GENE AMPLIFICATION; GENE LOCUS; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; METASTASIS; METASTATIC MELANOMA; NOS1 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADOPTIVE TRANSFER; CELL LINE, TUMOR; COCULTURE TECHNIQUES; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; NEOPLASM PROTEINS; NITRIC OXIDE SYNTHASE TYPE I; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 84899728545     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69611     Document Type: Article

References (42)

1. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007;4(5):e176.
2. Lesinski GB, et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst. 2004;96(17):1331-1342.
3. Mortarini R, et al. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res. 2009;15(12):4085-4094.
4. Critchley-Thorne RJ, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009;106(22):9010-9015.
5. Simons DL, Lee G, Kirkwood JM, Lee PP. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after highdose interferon therapy in melanoma patients. J Transl Med. 2011;9:52.
6. Zimmerer JM, et al. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN. Clin Cancer Res. 2008;14(18):5900-5906.
7. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumors: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
8. Ascierto ML, et al. An immunologic portrait of cancer. J Transl Med. 2011;9:146.
9. Lesinski GB, et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN- compared with immune effector cells. Clin Cancer Res. 2007;13(17):5010-5019.
10. Thompson FH, et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet. 1995;83(2):93-104.
11. Jonsson G, et al. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene. 2007;26(32):4738-4748.
12. Roschke AV, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 2003;63(24):8634-8647.
13. Spivey TL, et al. The stable traits of melanoma genetics: an alternative approach to target discovery. BMC Genomics. 2012;13:156.
14. Weiss G, et al. Molecular insights on the peripheral and intra-tumoral effects of systemic high dose rIL-2 (Aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res. 2011;17(23):7440-7450.
15. Dudley ME, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010; 16(24):6122-6131.
16. Rosenberg SA, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-4557.
17. Galon J, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1.
18. Lloyd OC. Regression of malignant melanoma as a manifestation of a cellular immunity response. Proc R Soc Med. 1969;62(6):543-545.
19. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol. 1969;97(3):459-468.
20. Pages F, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654-2666.
21. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964.
22. Tosolini M, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011;71(4):1263-1271.
23. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol. 2008;29(6):256-262.
24. Wang E, Tomei S, Marincola FM. Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunol Immunother. 2012;61(6):761-770.
25. Wang E, Uccellini L, Marincola FM. A genetic inference on cancer immune responsiveness. Oncoimmunology. 2012;1(4):520-525.
26. Zea AH, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1995;1(11):1327-1335.
27. Zea AH, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005; 65(8):3044-3048.
28. Lee PP, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5(6):677-685.
29. Huber V, Filipazzi P, Iero M, Fais S, Rivoltini L. More insights into the immunosuppressive potential of tumor exosomes. J Transl Med. 2008;6:63.
30. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006; 16(1):3-15.
31. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61(2):255-263.
32. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther. 2012;12(10):1383-1397.
33. Cormier JN, et al. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer. 1999;80(5):781-790.
34. Sabatino M, et al. Conservation of a core of genetic alterations over a decade of recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 2008;68(1):122-131.
35. Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. 1997;57(5):978-987.
36. Cheng F, et al. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003;19(3):425-436.
37. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem. 2006;281(20):14111-14118.
38. Wang W, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFN2b. Clin Cancer Res. 2007;13(5):1523-1531.
39. Atreya R, Neurath MF. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets. 2008;9(5):369-374.
40. Glynn SA, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010;120(11):3843-3854.
41. Switzer CH, et al. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci. 2011;32(11):644-651.
42. Pos Z, et al. Genomic scale analysis of racial impact on response to IFN. Proc Natl Acad Sci U S A. 2010;107(2):803-808.